九部门发文鼓励创新药进药店！港股通创新药大反攻，520880急速冲上2%！逾2亿元资金提前埋伏

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing a strong rebound, driven by a new policy aimed at promoting the retail drug industry and enhancing the accessibility of innovative drugs [3][9]. Group 1: Market Performance - On January 23, the Hong Kong Stock Connect innovative drug ETF (520880) surged by 2%, with leading stocks such as Cloudtop and InnoCare Biologics showing significant gains [1][8]. - The ETF has seen over 230 million yuan in net subscriptions this week, bringing its total shares to 4.538 billion, a new historical high [3][9]. Group 2: Policy Impact - A new policy issued by the Ministry of Commerce and other departments encourages the sale of innovative drugs and reference preparations in retail pharmacies, aiming to improve the purchasing experience [3][9]. - The policy is designed to enhance the professional service capabilities of the retail drug sector and provide pathways for high-value innovative drugs, such as CAR-T, to fill insurance coverage gaps [3][9]. Group 3: ETF Characteristics - The Hong Kong Stock Connect innovative drug ETF (520880) tracks an index that has three unique advantages: it exclusively covers innovative drug companies, has a high concentration of leading firms, and manages risks associated with less liquid stocks [5][11]. - The top ten stocks in the ETF account for over 73% of its weight, indicating a strong representation of leading innovative drug companies [6][13].